welcome
Reuters

Reuters

Health

Health

J&J beats quarterly sales and profit estimates on cancer drug sales

Reuters
Summary
Nutrition label

78% Informative

J&J has been on an acquisition spree to boost its drugs and device businesses after spinning off its consumer unit in 2023 .

The company expects 2025 sales of between $90.9 billion and $91.7 billion .

Last week , it announced the Intra-Cellular acquisition - its biggest deal in two years .